Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $5.17 and last traded at $5.20, with a volume of 24026 shares traded. The stock had previously closed at $5.34.
Analyst Upgrades and Downgrades
Separately, Sanford C. Bernstein raised Elekta AB (publ) from a "strong sell" rating to a "hold" rating in a report on Wednesday, January 29th.
Read Our Latest Report on Elekta AB (publ)
Elekta AB (publ) Price Performance
The company has a current ratio of 1.05, a quick ratio of 0.81 and a debt-to-equity ratio of 0.60. The business's 50-day simple moving average is $5.73 and its two-hundred day simple moving average is $5.91. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 21.08 and a beta of 1.25.
Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Elekta AB (publ) had a return on equity of 11.07% and a net margin of 5.65%. The firm had revenue of $416.86 million for the quarter, compared to analyst estimates of $435.89 million. As a group, research analysts expect that Elekta AB will post 0.36 EPS for the current fiscal year.
Elekta AB (publ) Cuts Dividend
The firm also recently disclosed a dividend, which was paid on Thursday, March 27th. Stockholders of record on Friday, March 7th were given a $0.1072 dividend. The ex-dividend date of this dividend was Friday, March 7th. Elekta AB (publ)'s dividend payout ratio (DPR) is presently 44.00%.
Elekta AB (publ) Company Profile
(
Get Free Report)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.
See Also
Before you consider Elekta AB (publ), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.
While Elekta AB (publ) currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.